Pseudoephedrine (English Wikipedia)

Weiss BD (15 January 2005). "Selecting Medications for the Treatment of Urinary Incontinence – January 15, 2005 – American Family Physician". American Family Physician. 71 (2): 315–322. Archived from the original on 7 July 2022. Retrieved 6 May 2012.
Culligan PJ, Heit M (December 2000). "Urinary incontinence in women: evaluation and management". American Family Physician. 62 (11): 2433–44, 2447, 2452. PMID 11130230. Archived from the original on 7 September 2023. Retrieved 7 September 2023.

aic.gov.au

"Trends & issues in crime and criminal justice No. 509, March 2016" (PDF). Australian Institute of Criminology. 7 March 2016. Retrieved 11 July 2024.

apu.fi

"Kysy Kiminkiseltä: Parasta flunssan hoitoa on lepo ja mummon mustaviinimarjamehu". www.apu.fi. 29 January 2018. Archived from the original on 9 July 2023. Retrieved 9 July 2023.

aspetjournals.org

jpet.aspetjournals.org

Patil PN, Tye A, Lapidus JB (May 1965). "A Pharmacological Study of the Ephedrine Isomers". The Journal of Pharmacology and Experimental Therapeutics. 148 (2): 158–168. PMID 14301006. Archived from the original on 7 January 2020. Retrieved 24 December 2009.

auanet.org

"American Urological Association – Medical Student Curriculum – Urinary Incontinence". American Urological Association. Archived from the original on 9 July 2015. Retrieved 12 August 2015.

bcfi.be

"(Pseudo-)efedrine en fusidinezuur vanaf 1 november enkel nog op voorschrift!". Belgisch centrum voor farmacotherapeutische informatie. 24 October 2024. Retrieved 2 December 2024.

biomedicalpublications.com

Baselt R (2008). Disposition of Toxic Drugs and Chemicals in Man (8th ed.). Foster City, California: Biomedical Publications. pp. 1344–1346. Archived from the original on 4 December 2020. Retrieved 19 August 2010.

books.google.com

Kizior R, Hodgson BB (2014). Saunders Nursing Drug Handbook 2015 - E-Book: Saunders Nursing Drug Handbook 2015 - E-Book. Elsevier Health Sciences. p. 1016. ISBN 978-0-323-28018-1. Retrieved 14 July 2024.
Braun DD (2012). Over the Counter Pharmaceutical Formulations. Elsevier Science. p. 181. ISBN 978-0-8155-1849-5. Retrieved 26 July 2024.
Berry TM (2001). Nursing Nonprescription Drug Handbook. Nursing Drug Handbook Series. Springhouse. p. 114. ISBN 978-1-58255-101-2. Retrieved 14 July 2024.
Elks J (2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer US. p. 793. ISBN 978-1-4757-2085-3. Retrieved 25 July 2024.
Schweizerischer Apotheker-Verein (2000). Index Nominum 2000: International Drug Directory. Medpharm Scientific Publishers. p. 896. ISBN 978-3-88763-075-1. Retrieved 25 July 2024.
Morton IK, Hall JM (2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Netherlands: Springer. p. 239. ISBN 978-94-011-4439-1. Retrieved 25 July 2024.
Wallechinsky D (2009). Complete Book of the Winter Olympics. Greystone Books. ISBN 978-1-55365-502-2. Retrieved 9 July 2010.

bp.blogspot.com

1.bp.blogspot.com

"Photographic image of Congestal tablets information sheet" (JPG). 1.bp.blogspot.com. Archived from the original on 13 December 2018. Retrieved 28 February 2022.

cbc.ca

"Silken tests positive". Archived from the original on 4 March 2014. Retrieved 24 February 2014.

ccheadliner.com

"Ozark passes pseudoephedrine ban: Drug now prescription-only". CCHeadliner.com. 18 June 2013. Archived from the original on 24 February 2021. Retrieved 17 December 2013.

clincalc.com

"The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
"Brompheniramine; Dextromethorphan; Pseudoephedrine Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.
"Loratadine; Pseudoephedrine Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.

doi.org

Głowacka K, Wiela-Hojeńska A (May 2021). "Pseudoephedrine—Benefits and Risks". Int J Mol Sci. 22 (10): 5146. doi:10.3390/ijms22105146. PMC 8152226. PMID 34067981.
Eccles R (January 2007). "Substitution of phenylephrine for pseudoephedrine as a nasal decongeststant. An illogical way to control methamphetamine abuse". British Journal of Clinical Pharmacology. 63 (1): 10–14. doi:10.1111/j.1365-2125.2006.02833.x. PMC 2000711. PMID 17116124.
Volpp M, Holzgrabe U (January 2019). "Determination of plasma protein binding for sympathomimetic drugs by means of ultrafiltration". Eur J Pharm Sci. 127: 175–184. doi:10.1016/j.ejps.2018.10.027. PMID 30391401.
Schmidt S (2023). Lang-etablierte Arzneistoffe genauer unter die Lupe genommen: Enantioselektive Proteinbindung und Stabilitätsstudien [A closer look at long-established drugs: enantioselective protein binding and stability studies] (Thesis) (in German). Universität Würzburg. doi:10.25972/opus-34594.
Chua SS, Benrimoj SI, Triggs EJ (1989). "Pharmacokinetics of non-prescription sympathomimetic agents". Biopharm Drug Dispos. 10 (1): 1–14. doi:10.1002/bdd.2510100102. PMID 2647163.
Aaron CK (August 1990). "Sympathomimetics". Emerg Med Clin North Am. 8 (3): 513–526. doi:10.1016/S0733-8627(20)30256-X. PMID 2201518.
Laccourreye O, Werner A, Giroud JP, Couloigner V, Bonfils P, Bondon-Guitton E (February 2015). "Benefits, limits and danger of ephedrine and pseudoephedrine as nasal decongestants". Eur Ann Otorhinolaryngol Head Neck Dis. 132 (1): 31–34. doi:10.1016/j.anorl.2014.11.001. PMID 25532441.
Freeman R, Kaufmann H (2007). "Disorders of Orthostatic Tolerance—Orthostatic Hypotension, Postural Tachycardia Syndrome, and Syncope". Continuum: Lifelong Learning in Neurology. 13: 50–88. doi:10.1212/01.CON.0000299966.05395.6c. ISSN 1080-2371.
Van Berkel MA, Fuller LA, Alexandrov AW, Jones GM (2015). "Methylene blue, midodrine, and pseudoephedrine: a review of alternative agents for refractory hypotension in the intensive care unit". Crit Care Nurs Q. 38 (4): 345–358. doi:10.1097/CNQ.0000000000000086. PMID 26335214.
Fedorowski A (April 2019). "Postural orthostatic tachycardia syndrome: clinical presentation, aetiology and management". J Intern Med. 285 (4): 352–366. doi:10.1111/joim.12852. PMID 30372565.
Schifano F, Chiappini S, Miuli A, Mosca A, Santovito MC, Corkery JM, et al. (2021). "Focus on Over-the-Counter Drugs' Misuse: A Systematic Review on Antihistamines, Cough Medicines, and Decongestants". Front Psychiatry. 12: 657397. doi:10.3389/fpsyt.2021.657397. PMC 8138162. PMID 34025478.
Munafò A, Frara S, Perico N, Di Mauro R, Cortinovis M, Burgaletto C, et al. (December 2021). "In search of an ideal drug for safer treatment of obesity: The false promise of pseudoephedrine". Rev Endocr Metab Disord. 22 (4): 1013–1025. doi:10.1007/s11154-021-09658-w. PMC 8724077. PMID 33945051.
Trinh KV, Kim J, Ritsma A (2015). "Effect of pseudoephedrine in sport: a systematic review". BMJ Open Sport Exerc Med. 1 (1): e000066. doi:10.1136/bmjsem-2015-000066. PMC 5117033. PMID 27900142.
Gheorghiev MD, Hosseini F, Moran J, Cooper CE (October 2018). "Effects of pseudoephedrine on parameters affecting exercise performance: a meta-analysis". Sports Med Open. 4 (1): 44. doi:10.1186/s40798-018-0159-7. PMC 6173670. PMID 30291523.
Taverner D, Latte J (January 2007). Latte GJ (ed.). "Nasal decongestants for the common cold". Cochrane Database Syst Rev (1): CD001953. doi:10.1002/14651858.CD001953.pub3. PMID 17253470.
Salerno SM, Jackson JL, Berbano EP (2005). "Effect of oral pseudoephedrine on blood pressure and heart rate: a meta-analysis". Arch Intern Med. 165 (15): 1686–1694. doi:10.1001/archinte.165.15.1686. PMID 16087815.
Cantu C, Arauz A, Murillo-Bonilla LM, López M, Barinagarrementeria F (July 2003). "Stroke associated with sympathomimetics contained in over-the-counter cough and cold drugs". Stroke. 34 (7): 1667–1672. doi:10.1161/01.STR.0000075293.45936.FA. PMID 12791938.
Rothman RB, Vu N, Partilla JS, Roth BL, Hufeisen SJ, Compton-Toth BA, et al. (October 2003). "In vitro characterization of ephedrine-related stereoisomers at biogenic amine transporters and the receptorome reveals selective actions as norepinephrine transporter substrates". J Pharmacol Exp Ther. 307 (1): 138–145. doi:10.1124/jpet.103.053975. PMID 12954796.
O'Donnell SR (March 1995). "Sympathomimetic vasoconstrictors as nasal decongestants". Med J Aust. 162 (5): 264–267. doi:10.5694/j.1326-5377.1995.tb139882.x. PMID 7534374.
Bouchard R, Weber AR, Geiger JD (July 2002). "Informed decision-making on sympathomimetic use in sport and health". Clin J Sport Med. 12 (4): 209–224. doi:10.1097/00042752-200207000-00003. PMID 12131054.
Abourashed EA, El-Alfy AT, Khan IA, Walker L (August 2003). "Ephedra in perspective--a current review". Phytother Res. 17 (7): 703–712. doi:10.1002/ptr.1337. PMID 12916063.
Chen KK, Kao CH (1926). "Ephedrine and Pseudoephedrine, their Isolation, Constitution, Isomerism, Properties, Derivatives and Synthesis. (with a Bibliography) **The expense of this work has been defrayed by a part of a grant from the Committee on Therapeutic Research, Council on Pharmacy and Chemistry, American Medical Association". The Journal of the American Pharmaceutical Association (1912). 15 (8): 625–639. doi:10.1002/jps.3080150804.
Hatton RC, Hendeles L (March 2022). "Why Is Oral Phenylephrine on the Market After Compelling Evidence of Its Ineffectiveness as a Decongestant?". Ann Pharmacother. 56 (11): 1275–1278. doi:10.1177/10600280221081526. PMID 35337187. S2CID 247712448.
Hendeles L, Hatton RC (July 2006). "Oral phenylephrine: an ineffective replacement for pseudoephedrine?". J Allergy Clin Immunol. 118 (1): 279–280. doi:10.1016/j.jaci.2006.03.002. PMID 16815167.
Minamizawa K, Goto H, Ohi Y, Shimada Y, Terasawa K, Haji A (September 2006). "Effect of d-pseudoephedrine on cough reflex and its mode of action in guinea pigs". Journal of Pharmacological Sciences. 102 (1): 136–142. doi:10.1254/jphs.FP0060526. PMID 16974066.
Sakai N, Chikahisa S, Nishino S (2010). "Stimulants in Excessive Daytime Sleepiness". Sleep Medicine Clinics. 5 (4): 591–607. doi:10.1016/j.jsmc.2010.08.009.
Takenoshita S, Nishino S (June 2020). "Pharmacologic Management of Excessive Daytime Sleepiness". Sleep Med Clin. 15 (2): 177–194. doi:10.1016/j.jsmc.2020.02.006. PMID 32386693.
Boutrel B, Koob GF (September 2004). "What keeps us awake: the neuropharmacology of stimulants and wakefulness-promoting medications". Sleep. 27 (6): 1181–1194. doi:10.1093/sleep/27.6.1181. PMID 15532213.
Sherkat AA, Sardana N, Safaee S, Lehman EB, Craig TJ (February 2011). "The role of pseudoephedrine on daytime somnolence in patients suffering from perennial allergic rhinitis (PAR)". Ann Allergy Asthma Immunol. 106 (2): 97–102. doi:10.1016/j.anai.2010.11.013. PMID 21277510.
Gelotte CK, Albrecht HH, Hynson J, Gallagher V (December 2019). "A Multicenter, Randomized, Placebo-Controlled Study of Pseudoephedrine for the Temporary Relief of Nasal Congestion in Children With the Common Cold". J Clin Pharmacol. 59 (12): 1573–1583. doi:10.1002/jcph.1472. PMC 6851811. PMID 31274197.
Greenway F, Herber D, Raum W, Herber D, Morales S (July 1999). "Double-blind, randomized, placebo-controlled clinical trials with non-prescription medications for the treatment of obesity". Obes Res. 7 (4): 370–378. doi:10.1002/j.1550-8528.1999.tb00420.x. PMID 10440593.
Coulter AA, Rebello CJ, Greenway FL (July 2018). "Centrally Acting Agents for Obesity: Past, Present, and Future". Drugs. 78 (11): 1113–1132. doi:10.1007/s40265-018-0946-y. PMC 6095132. PMID 30014268.
Ioannides-Demos LL, Proietto J, McNeil JJ (2005). "Pharmacotherapy for obesity". Drugs. 65 (10): 1391–418. doi:10.2165/00003495-200565100-00006. PMID 15977970.
Fedorowski A, Melander O (April 2013). "Syndromes of orthostatic intolerance: a hidden danger". J Intern Med. 273 (4): 322–335. doi:10.1111/joim.12021. PMID 23216860.
Abed H, Ball PA, Wang LX (March 2012). "Diagnosis and management of postural orthostatic tachycardia syndrome: A brief review". J Geriatr Cardiol. 9 (1): 61–67. doi:10.3724/SP.J.1263.2012.00061. PMC 3390096. PMID 22783324.
Muneer A, Minhas S, Arya M, Ralph DJ (August 2008). "Stuttering priapism--a review of the therapeutic options". Int J Clin Pract. 62 (8): 1265–1270. doi:10.1111/j.1742-1241.2008.01780.x. PMID 18479367.
Deckx L, De Sutter AI, Guo L, Mir NA, van Driel ML (October 2016). "Nasal decongestants in monotherapy for the common cold". The Cochrane Database of Systematic Reviews. 2016 (10): CD009612. doi:10.1002/14651858.CD009612.pub2. PMC 6461189. PMID 27748955.
Hughes DT, Empey DW, Land M (December 1983). "Effects of pseudoephedrine in man". J Clin Hosp Pharm. 8 (4): 315–321. doi:10.1111/j.1365-2710.1983.tb01053.x. PMID 6198336.
Vidal C, Prieto A, Pérez-Carral C, Armisén M (April 1998). "Nonpigmenting fixed drug eruption due to pseudoephedrine". Annals of Allergy, Asthma & Immunology. 80 (4): 309–310. doi:10.1016/S1081-1206(10)62974-2. PMID 9564979.
Webb J, Dubose J (2013). "Symptoms of major depression after pseudoephedrine withdrawal: a case report". J Neuropsychiatry Clin Neurosci. 25 (2): E54–E55. doi:10.1176/appi.neuropsych.12060138. PMID 23686066.
Freeman KB, Wang Z, Woolverton WL (April 2010). "Self-administration of (+)-methamphetamine and (+)-pseudoephedrine, alone and combined, by rhesus monkeys". Pharmacol Biochem Behav. 95 (2): 198–202. doi:10.1016/j.pbb.2010.01.005. PMC 2838499. PMID 20100506.
Wee S, Ordway GA, Woolverton WL (June 2004). "Reinforcing effect of pseudoephedrine isomers and the mechanism of action". Eur J Pharmacol. 493 (1–3): 117–125. doi:10.1016/j.ejphar.2004.04.030. PMID 15189772.
Tongjaroenbuangam W, Meksuriyen D, Govitrapong P, Kotchabhakdi N, Baldwin BA (February 1998). "Drug discrimination analysis of pseudoephedrine in rats". Pharmacol Biochem Behav. 59 (2): 505–510. doi:10.1016/s0091-3057(97)00459-0. PMID 9477001.
Akiba K, Satoh S, Matsumura H, Suzuki T, Kohno H, Tadano T, et al. (May 1982). "[Effect of d-pseudoephedrine on the central nervous system in mice]". Nihon Yakurigaku Zasshi (in Japanese). 79 (5): 401–408. doi:10.1254/fpj.79.401. PMID 6813205.
Diaz MA, Wise TN, Semchyshyn GO (September 1979). "Self-medication with pseudoephedrine in a chronically depressed patient". Am J Psychiatry. 136 (9): 1217–1218. doi:10.1176/ajp.136.9.1217. PMID 474820.
Stalker DJ, Jungbluth GL (2003). "Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial". Clin Pharmacokinet. 42 (13): 1129–1140. doi:10.2165/00003088-200342130-00004. PMID 14531724.
Jacob JE, Wagner ML, Sage JI (March 2003). "Safety of selegiline with cold medications". Ann Pharmacother. 37 (3): 438–441. doi:10.1345/aph.1C175. PMID 12639177.
Hendershot PE, Antal EJ, Welshman IR, Batts DH, Hopkins NK (May 2001). "Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorpan HBr". J Clin Pharmacol. 41 (5): 563–572. doi:10.1177/00912700122010302. PMID 11361053.
Azzaro AJ, VanDenBerg CM, Ziemniak J, Kemper EM, Blob LF, Campbell BJ (August 2007). "Evaluation of the potential for pharmacodynamic and pharmacokinetic drug interactions between selegiline transdermal system and two sympathomimetic agents (pseudoephedrine and phenylpropanolamine) in healthy volunteers". J Clin Pharmacol. 47 (8): 978–990. doi:10.1177/0091270007302950. PMID 17554106.
Johnson DA, Hricik JG (1993). "The pharmacology of alpha-adrenergic decongestants". Pharmacotherapy. 13 (6 Pt 2): 110S–115S, discussion 143S–146S. doi:10.1002/j.1875-9114.1993.tb02779.x. PMID 7507588.
Broadley KJ (March 2010). "The vascular effects of trace amines and amphetamines". Pharmacol Ther. 125 (3): 363–375. doi:10.1016/j.pharmthera.2009.11.005. PMID 19948186. It is also relevant to other sympathomimetic amines contained in over-the-counter cough and cold remedies as decongestants, such as phenylpropanolamine and pseudoephedrine. Thus, MAO inhibitors potentiate the peripheral effects of indirectly acting sympathomimetic amines. It is not often realized, however, that this potentiation occurs irrespective of whether the amine is a substrate for MAO. An α-methyl group on the side chain, as in amphetamine and ephedrine, renders the amine immune to deamination so that they are not metabolized in the gut. Similarly, β-PEA would not be deaminated in the gut as it is a selective substrate for MAO-B which is not found in the gut. However, MAO inhibition in sympathetic neurones allows the cytoplasmic pool of noradrenaline to increase. It is this pool that is released by indirectly acting sympathomimetic amines and their responses are therefore potentiated irrespective of whether they are deaminated by MAO (Youdim & Finberg, 1991).
Marcucci C (2015). "Too Young to Die". A Case Approach to Perioperative Drug-Drug Interactions. New York, NY: Springer New York. pp. 543–545. doi:10.1007/978-1-4614-7495-1_120. ISBN 978-1-4614-7494-4.
Mariani PJ (March 1986). "Pseudoephedrine-induced hypertensive emergency: treatment with labetalol". Am J Emerg Med. 4 (2): 141–142. doi:10.1016/0735-6757(86)90159-2. PMID 3947442.
Mores N, Campia U, Navarra P, Cardillo C, Preziosi P (June 1999). "No cardiovascular effects of single-dose pseudoephedrine in patients with essential hypertension treated with beta-blockers". Eur J Clin Pharmacol. 55 (4): 251–254. doi:10.1007/s002280050624. PMID 10424315.
Patrick KS, Markowitz JS (1997). "Pharmacology of methylphenidate, amphetamine enantiomers and pemoline in attention-deficit hyperactivity disorder". Human Psychopharmacology: Clinical and Experimental. 12 (6): 527–546. doi:10.1002/(SICI)1099-1077(199711/12)12:6<527::AID-HUP932>3.0.CO;2-U. ISSN 0885-6222.
Abraham DJ (15 January 2003). Burger's Medicinal Chemistry and Drug Discovery. Wiley. doi:10.1002/0471266949.bmc093. ISBN 978-0-471-26694-5.
Gad MZ, Azab SS, Khattab AR, Farag MA (October 2021). "Over a century since ephedrine discovery: an updated revisit to its pharmacological aspects, functionality and toxicity in comparison to its herbal extracts". Food Funct. 12 (20): 9563–9582. doi:10.1039/d1fo02093e. PMID 34533553.
Kobayashi S, Endou M, Sakuraya F, Matsuda N, Zhang XH, Azuma M, et al. (November 2003). "The sympathomimetic actions of l-ephedrine and d-pseudoephedrine: direct receptor activation or norepinephrine release?". Anesth Analg. 97 (5): 1239–1245. doi:10.1213/01.ANE.0000092917.96558.3C. PMID 14570629.
Rothman RB, Baumann MH (2003). "Monoamine transporters and psychostimulant drugs". Eur. J. Pharmacol. 479 (1–3): 23–40. doi:10.1016/j.ejphar.2003.08.054. PMID 14612135.
Rothman RB, Baumann MH (2006). "Therapeutic potential of monoamine transporter substrates". Curr Top Med Chem. 6 (17): 1845–1859. doi:10.2174/156802606778249766. PMID 17017961.
Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, et al. (January 2001). "Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin". Synapse. 39 (1): 32–41. doi:10.1002/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3. PMID 11071707.
Baumann MH, Partilla JS, Lehner KR, Thorndike EB, Hoffman AF, Holy M, et al. (2013). "Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products". Neuropsychopharmacology. 38 (4): 552–562. doi:10.1038/npp.2012.204. PMC 3572453. PMID 23072836.
Baumann MH, Ayestas MA, Partilla JS, Sink JR, Shulgin AT, Daley PF, et al. (April 2012). "The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue". Neuropsychopharmacology. 37 (5): 1192–203. doi:10.1038/npp.2011.304. PMC 3306880. PMID 22169943.
Rothman RB, Baumann MH (December 2005). "Targeted screening for biogenic amine transporters: potential applications for natural products". Life Sci. 78 (5): 512–518. doi:10.1016/j.lfs.2005.09.001. PMID 16202429.
Vansal SS, Feller DR (September 1999). "Direct effects of ephedrine isomers on human beta-adrenergic receptor subtypes". Biochem Pharmacol. 58 (5): 807–810. doi:10.1016/s0006-2952(99)00152-5. PMID 10449190.
Drew CD, Knight GT, Hughes DT, Bush M (September 1978). "Comparison of the effects of D-(-)-ephedrine and L-(+)-pseudoephedrine on the cardiovascular and respiratory systems in man". British Journal of Clinical Pharmacology. 6 (3): 221–225. doi:10.1111/j.1365-2125.1978.tb04588.x. PMC 1429447. PMID 687500.
Ulus IH, Maher TJ, Wurtman RJ (June 2000). "Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors". Biochem Pharmacol. 59 (12): 1611–1621. doi:10.1016/s0006-2952(00)00306-3. PMID 10799660.
Sequeira RP N (1998). "Central nervous system stimulants and drugs that suppress appetite". Side Effects of Drugs Annual. Vol. 21. Elsevier. p. 1–8. doi:10.1016/s0378-6080(98)80005-6. ISBN 978-0-444-82818-7.
Sica DA, Comstock TJ (October 1989). "Pseudoephedrine accumulation in renal failure". Am J Med Sci. 298 (4): 261–263. doi:10.1097/00000441-198910000-00010. PMID 2801760.
Lyon CC, Turney JH (1996). "Pseudoephedrine toxicity in renal failure". Br J Clin Pract. 50 (7): 396–397. doi:10.1111/j.1742-1241.1996.tb09584.x. PMID 9015914.
Kril MB, Fung HL (May 1990). "Influence of hydrophobicity on the ion exchange selectivity coefficients for aromatic amines". J Pharm Sci. 79 (5): 440–443. doi:10.1002/jps.2600790517. PMID 2352166.
Bharate SS, Mignani S, Vishwakarma RA (December 2018). "Why Are the Majority of Active Compounds in the CNS Domain Natural Products? A Critical Analysis". J Med Chem. 61 (23): 10345–10374. doi:10.1021/acs.jmedchem.7b01922. PMID 29989814.
Schep LJ, Slaughter RJ, Beasley DM (August 2010). "The clinical toxicology of metamfetamine". Clin Toxicol (Phila). 48 (7): 675–694. doi:10.3109/15563650.2010.516752. PMID 20849327. Metamfetamine acts in a manner similar to amfetamine, but with the addition of the methyl group to the chemical structure. It is more lipophilic (Log p value 2.07, compared with 1.76 for amfetamine),⁴ thereby enabling rapid and extensive transport across the blood–brain barrier.¹⁹
Froese L, Dian J, Gomez A, Unger B, Zeiler FA (October 2020). "The cerebrovascular response to norepinephrine: A scoping systematic review of the animal and human literature". Pharmacol Res Perspect. 8 (5): e00655. doi:10.1002/prp2.655. PMC 7510331. PMID 32965778.
Pajouhesh H, Lenz GR (October 2005). "Medicinal chemical properties of successful central nervous system drugs". NeuroRx. 2 (4): 541–553. doi:10.1602/neurorx.2.4.541. PMC 1201314. PMID 16489364. Lipophilicity was the first of the descriptors to be identified as important for CNS penetration. Hansch and Leo54 reasoned that highly lipophilic molecules will partitioned into the lipid interior of membranes and will be retained there. However, ClogP correlates nicely with LogBBB with increasing lipophilicity increasing brain penetration. For several classes of CNS active substances, Hansch and Leo54 found that blood-brain barrier penetration is optimal when the LogP values are in the range of 1.5-2.7, with the mean value of 2.1. An analysis of small drug-like molecules suggested that for better brain permeation46 and for good intestinal permeability55 the LogD values need to be greater than 0 and less than 3. In comparison, the mean value for ClogP for the marketed CNS drugs is 2.5, which is in good agreement with the range found by Hansch et al.22
Boland DM, Rein J, Lew EO, Hearn WL (October 2003). "Fatal cold medication intoxication in an infant". Journal of Analytical Toxicology. 27 (7): 523–526. doi:10.1093/jat/27.7.523. PMID 14607011.
Oliver AL, Anderson BN, Roddick FA (1999). "Factors affecting the production of L-phenylacetylcarbinol by yeast: a case study". Advances in Microbial Physiology. Vol. 41. pp. 1–45. doi:10.1016/S0065-2911(08)60164-2. ISBN 978-0-12-027741-4. PMID 10500843.
Kalix P (April 1991). "The pharmacology of psychoactive alkaloids from ephedra and catha". J Ethnopharmacol. 32 (1–3): 201–208. doi:10.1016/0378-8741(91)90119-x. PMID 1881158.
Ladenburg A, Oelschlägel C (1889). "Ueber das "Pseudo-Ephedrin"" [On pseudo-ephedrine]. Berichte der Deutschen Chemischen Gesellschaft (in German). 22 (2): 1823–1827. doi:10.1002/cber.18890220225. Archived from the original on 8 March 2021. Retrieved 19 May 2019.
Strano-Rossi S, Leone D, de la Torre X, Botrè F (August 2009). "The relevance of the urinary concentration of ephedrines in anti-doping analysis: determination of pseudoephedrine, cathine, and ephedrine after administration of over-the-counter medicaments". Therapeutic Drug Monitoring. 31 (4): 520–526. doi:10.1097/FTD.0b013e3181ac6006. PMID 19571776. S2CID 21333203.
Jolley D, Dawson B, Maloney SK, White J, Goodman C, Peeling P (June 2014). "Hydration and urinary pseudoephedrine levels after a simulated team game". International Journal of Sport Nutrition and Exercise Metabolism. 24 (3): 325–332. doi:10.1123/ijsnem.2013-0076. PMID 24458099.
Hatton RC, Winterstein AG, McKelvey RP, Shuster J, Hendeles L (March 2007). "Efficacy and safety of oral phenylephrine: systematic review and meta-analysis". The Annals of Pharmacotherapy. 41 (3): 381–390. doi:10.1345/aph.1H679. PMID 17264159. S2CID 25627664.
Horak F, Zieglmayer P, Zieglmayer R, Lemell P, Yao R, Staudinger H, et al. (February 2009). "A placebo-controlled study of the nasal decongestant effect of phenylephrine and pseudoephedrine in the Vienna Challenge Chamber". Annals of Allergy, Asthma & Immunology. 102 (2): 116–120. doi:10.1016/S1081-1206(10)60240-2. PMID 19230461.
Achuthan S, Medhi B (September 2015). "A systematic review of the pharmacological approaches against snoring: can we count on the chickens that have hatched?". Sleep Breath. 19 (3): 1035–1042. doi:10.1007/s11325-015-1123-0. PMID 25680547.
Trimeloni L, Spencer J (2016). "Diagnosis and Management of Breast Milk Oversupply". J Am Board Fam Med. 29 (1): 139–142. doi:10.3122/jabfm.2016.01.150164. PMID 26769886.
Aljazaf K, Hale TW, Ilett KF, Hartmann PE, Mitoulas LR, Kristensen JH, et al. (July 2003). "Pseudoephedrine: effects on milk production in women and estimation of infant exposure via breastmilk". British Journal of Clinical Pharmacology. 56 (1): 18–24. doi:10.1046/j.1365-2125.2003.01822.x. PMC 1884328. PMID 12848771.

drugbank.com

go.drugbank.com

"Pseudoephedrine: Uses, Interactions, Mechanism of Action". DrugBank Online. 1 October 1994. Retrieved 25 July 2024.

drugpamphlet.blogspot.com

"Drug Pamphlet: Congestal". 12 February 2017. Archived from the original on 13 December 2018. Retrieved 13 December 2018.

eltiempo.com

"Gobierno prohĂbe antigripales con pseudoefedrina a partir de finales de 2010 – Archivo – Archivo Digital de Noticias de Colombia y el Mundo desde 1.990" [Government Prohibits Flu Pseudoephedrine in Late 2010 – Archive – News Archive Digital Colombia and the World since 1990] (in Spanish). Eltiempo.com. 8 July 2009 [Published 11 August 2009]. Archived from the original on 21 May 2011. Retrieved 6 May 2012.

eluniversal.com.mx

"Prohibirán definitivamente uso de pseudoefedrina" [A Permanent Ban on Pseudoephedrine] (in Spanish). 23 November 2007 [Published 2 December 2007]. Archived from the original on 19 December 2013. Retrieved 17 December 2013.

emb-japan.go.jp

seattle.us.emb-japan.go.jp

"Customs Information". Consulate-General of Japan in Seattle. Archived from the original on 19 August 2015. Retrieved 27 August 2015.

emissourian.com

"Council Passes Law Restricting Pseudoephedrine". The Washington Missourian. 7 July 2009. Archived from the original on 12 March 2012. Retrieved 10 December 2010.
"Union Board Approves Pseudoephedrine Ordinance". The Washington Missourian. 13 October 2009. Archived from the original on 12 March 2012. Retrieved 10 December 2010.
"New Haven Passes Prescription Law". The Washington Missourian. 11 November 2010. Archived from the original on 12 March 2012. Retrieved 10 December 2010.

fagg-afmps.be

"Geneesmiddelen met de werkzame bestanddelen (pseudo-)efedrine en fusidinezuur zijn in België vanaf 1 november 2024 voorschriftplichtig". Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten. 30 September 2024. Retrieved 2 December 2024.

famhp.be

"PRAC February 2023 – Start of a safety review of pseudoephedrine-containing medicines | FAMHP". www.famhp.be. Archived from the original on 15 August 2023. Retrieved 15 August 2023.

familyhealthonline.ca

"Family Health Online – Family Health Magazine -PHARMACY CARE – Over-the-Counter Medication – Why must I ask for that?". Archived from the original on 18 June 2016. Retrieved 18 August 2016.

fda.gov

accessdata.fda.gov

"Drugs@FDA: FDA-Approved Drugs". accessdata.fda.gov. Food and Drug Administration. Retrieved 14 July 2024.

fda.gov

"Legal Requirements for the Sale and Purchase of Drug Products Containing Pseudoephedrine, Ephedrine, and Phenylpropanolamine". U.S. Food and Drug Administration. 9 March 2006. Archived from the original on 25 December 2023. Retrieved 7 September 2023. This article incorporates text from this source, which is in the public domain.

go.com

assets.espn.go.com

"Summer Olympics 2000 Raducan tests positive for stimulant". ESPN. 26 September 2000. Archived from the original on 2 October 2011. Retrieved 6 May 2012.

guild.org.au

"Project STOP A Pharmacy Guild Initiative, May 2016" (PDF). The Pharmacy Guild of Australia. 18 May 2016.

hathitrust.org

babel.hathitrust.org

Ladenburg A, Oelschlägel C (1889). "Ueber das "Pseudo-Ephedrin"" [On pseudo-ephedrine]. Berichte der Deutschen Chemischen Gesellschaft (in German). 22 (2): 1823–1827. doi:10.1002/cber.18890220225. Archived from the original on 8 March 2021. Retrieved 19 May 2019.

healthycanadians.gc.ca

"Archived – Health Canada Reminds Canadians not to use Ephedra/Ephedrine Products". healthycanadians.gc.ca. 20 August 2021. Archived from the original on 27 April 2014. Retrieved 1 July 2015.

house.gov

"Clamp down on shipments of raw ingredients, Oregonian, Press, Congressional Caucus to Fight and Control Methamphetamine". U.S. House of Representatives. 31 August 2005. Archived from the original on 9 May 2006. Retrieved 7 September 2023.

iceskatingintnl.com

"2000 World Championships – Pairs". Ice Skating International. Archived from the original on 14 November 2011. Retrieved 6 June 2010.

in-pharmatechnologist.com

Megget K (2 September 2007). "Pseudoephedrine drugs still OTC". Archived from the original on 29 August 2021. Retrieved 15 October 2018.

in.gov.br

Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 15 August 2023.

incb.org

"Microsoft Word - RedListE2007.doc" (PDF). Archived from the original (PDF) on 27 February 2008. Retrieved 6 May 2012.

innovationrx.com.au

"Project STOP video – Online Advertising". Innovationrx.com.au. Archived from the original on 26 April 2012. Retrieved 6 May 2012.

intekom.com

home.intekom.com

"Adco-Tussend". Home.intekom.com. 15 March 1993. Archived from the original on 30 April 2012. Retrieved 6 May 2012.

intlgymnast.com

"Amanar Tops Romanian Money List". International Gymnast Magazine Online. 15 October 2000. Archived from the original on 15 July 2001. Retrieved 6 May 2012.

istanbulsaglik.gov.tr

"Kontrole Tabi İlaçlar" (PDF). Social Security Institution of Republic of Turkey. July 2013. Archived from the original (PDF) on 11 March 2014. Retrieved 11 March 2014.

journalstar.com

"Nebraskans to sign for Sudafed". Lincoln Journal-Star. 13 March 2006. Archived from the original on 22 June 2018. Retrieved 20 August 2012.

justice.gov

"DEA, Maps of Methamphetamine Lab Incidents". Justice.gov. Archived from the original on 10 September 2012. Retrieved 6 May 2012.

listener.co.nz

"Chemical Brothers". Listener (New Zealand). Archived from the original on 23 May 2010.

medicines.org.uk

"Benadryl Allergy Relief Plus Decongestant Capsules - Summary of Product Characteristics (SmPC) - (emc)". www.medicines.org.uk. Datapharm. Archived from the original on 22 November 2023. Retrieved 22 November 2023.

medsafe.govt.nz

"Ephedrine and Pseudoephedrine to Become Controlled Drugs". Medsafe, New Zealand Medicines and Medical Devices Safety Authority. Archived from the original on 8 March 2007.

mhra.gov.uk

"Drug Safety Update, March 2008". The Medicines and Healthcare products Regulatory Agency and the Commission on Human Medicines. 30 June 2008. Archived from the original (PDF) on 14 June 2011.

namsdl.org

"State Ephedrine and Pseudoephedrine Single Over-The-Counter Transaction Limits". Namsdl.org. National Alliance for Model State Drug Laws (NAMSDL). 2013. Archived from the original (PDF) on 14 April 2016. Retrieved 3 December 2016.
"State Daily Gram Limits for Over-The-Counter Transactions Involving Ephedrine and Pseudoephedrine". Namsdl.org. National Alliance for Model State Drug Laws (NAMSDL). 2013. Archived from the original (PDF) on 14 August 2016. Retrieved 3 December 2016.
"State 30 Day Gram Limits for Over-The-Counter Transactions Involving Ephedrine and Pseudoephedrine". Namsdl.org. National Alliance for Model State Drug Laws (NAMSDL). 2013. Archived from the original (PDF) on 15 August 2016. Retrieved 3 December 2016.
"The National Alliance for Model State Drug Laws (NAMSDL) – Issues and Events". www.namsdl.org. Archived from the original on 3 October 2015. Retrieved 24 October 2015.

napra.ca

"Background on Update to NAPRA NHP Policy". napra.ca. 10 June 2024. Retrieved 11 July 2024.

nih.gov

pubmed.ncbi.nlm.nih.gov

Głowacka K, Wiela-Hojeńska A (May 2021). "Pseudoephedrine—Benefits and Risks". Int J Mol Sci. 22 (10): 5146. doi:10.3390/ijms22105146. PMC 8152226. PMID 34067981.
Eccles R (January 2007). "Substitution of phenylephrine for pseudoephedrine as a nasal decongeststant. An illogical way to control methamphetamine abuse". British Journal of Clinical Pharmacology. 63 (1): 10–14. doi:10.1111/j.1365-2125.2006.02833.x. PMC 2000711. PMID 17116124.
Volpp M, Holzgrabe U (January 2019). "Determination of plasma protein binding for sympathomimetic drugs by means of ultrafiltration". Eur J Pharm Sci. 127: 175–184. doi:10.1016/j.ejps.2018.10.027. PMID 30391401.
Chua SS, Benrimoj SI, Triggs EJ (1989). "Pharmacokinetics of non-prescription sympathomimetic agents". Biopharm Drug Dispos. 10 (1): 1–14. doi:10.1002/bdd.2510100102. PMID 2647163.
Aaron CK (August 1990). "Sympathomimetics". Emerg Med Clin North Am. 8 (3): 513–526. doi:10.1016/S0733-8627(20)30256-X. PMID 2201518.
Laccourreye O, Werner A, Giroud JP, Couloigner V, Bonfils P, Bondon-Guitton E (February 2015). "Benefits, limits and danger of ephedrine and pseudoephedrine as nasal decongestants". Eur Ann Otorhinolaryngol Head Neck Dis. 132 (1): 31–34. doi:10.1016/j.anorl.2014.11.001. PMID 25532441.
Van Berkel MA, Fuller LA, Alexandrov AW, Jones GM (2015). "Methylene blue, midodrine, and pseudoephedrine: a review of alternative agents for refractory hypotension in the intensive care unit". Crit Care Nurs Q. 38 (4): 345–358. doi:10.1097/CNQ.0000000000000086. PMID 26335214.
Fedorowski A (April 2019). "Postural orthostatic tachycardia syndrome: clinical presentation, aetiology and management". J Intern Med. 285 (4): 352–366. doi:10.1111/joim.12852. PMID 30372565.
Schifano F, Chiappini S, Miuli A, Mosca A, Santovito MC, Corkery JM, et al. (2021). "Focus on Over-the-Counter Drugs' Misuse: A Systematic Review on Antihistamines, Cough Medicines, and Decongestants". Front Psychiatry. 12: 657397. doi:10.3389/fpsyt.2021.657397. PMC 8138162. PMID 34025478.
Munafò A, Frara S, Perico N, Di Mauro R, Cortinovis M, Burgaletto C, et al. (December 2021). "In search of an ideal drug for safer treatment of obesity: The false promise of pseudoephedrine". Rev Endocr Metab Disord. 22 (4): 1013–1025. doi:10.1007/s11154-021-09658-w. PMC 8724077. PMID 33945051.
Trinh KV, Kim J, Ritsma A (2015). "Effect of pseudoephedrine in sport: a systematic review". BMJ Open Sport Exerc Med. 1 (1): e000066. doi:10.1136/bmjsem-2015-000066. PMC 5117033. PMID 27900142.
Gheorghiev MD, Hosseini F, Moran J, Cooper CE (October 2018). "Effects of pseudoephedrine on parameters affecting exercise performance: a meta-analysis". Sports Med Open. 4 (1): 44. doi:10.1186/s40798-018-0159-7. PMC 6173670. PMID 30291523.
Taverner D, Latte J (January 2007). Latte GJ (ed.). "Nasal decongestants for the common cold". Cochrane Database Syst Rev (1): CD001953. doi:10.1002/14651858.CD001953.pub3. PMID 17253470.
Salerno SM, Jackson JL, Berbano EP (2005). "Effect of oral pseudoephedrine on blood pressure and heart rate: a meta-analysis". Arch Intern Med. 165 (15): 1686–1694. doi:10.1001/archinte.165.15.1686. PMID 16087815.
Cantu C, Arauz A, Murillo-Bonilla LM, López M, Barinagarrementeria F (July 2003). "Stroke associated with sympathomimetics contained in over-the-counter cough and cold drugs". Stroke. 34 (7): 1667–1672. doi:10.1161/01.STR.0000075293.45936.FA. PMID 12791938.
Rothman RB, Vu N, Partilla JS, Roth BL, Hufeisen SJ, Compton-Toth BA, et al. (October 2003). "In vitro characterization of ephedrine-related stereoisomers at biogenic amine transporters and the receptorome reveals selective actions as norepinephrine transporter substrates". J Pharmacol Exp Ther. 307 (1): 138–145. doi:10.1124/jpet.103.053975. PMID 12954796.
O'Donnell SR (March 1995). "Sympathomimetic vasoconstrictors as nasal decongestants". Med J Aust. 162 (5): 264–267. doi:10.5694/j.1326-5377.1995.tb139882.x. PMID 7534374.
Bouchard R, Weber AR, Geiger JD (July 2002). "Informed decision-making on sympathomimetic use in sport and health". Clin J Sport Med. 12 (4): 209–224. doi:10.1097/00042752-200207000-00003. PMID 12131054.
Abourashed EA, El-Alfy AT, Khan IA, Walker L (August 2003). "Ephedra in perspective--a current review". Phytother Res. 17 (7): 703–712. doi:10.1002/ptr.1337. PMID 12916063.
Hatton RC, Hendeles L (March 2022). "Why Is Oral Phenylephrine on the Market After Compelling Evidence of Its Ineffectiveness as a Decongestant?". Ann Pharmacother. 56 (11): 1275–1278. doi:10.1177/10600280221081526. PMID 35337187. S2CID 247712448.
Hendeles L, Hatton RC (July 2006). "Oral phenylephrine: an ineffective replacement for pseudoephedrine?". J Allergy Clin Immunol. 118 (1): 279–280. doi:10.1016/j.jaci.2006.03.002. PMID 16815167.
Minamizawa K, Goto H, Ohi Y, Shimada Y, Terasawa K, Haji A (September 2006). "Effect of d-pseudoephedrine on cough reflex and its mode of action in guinea pigs". Journal of Pharmacological Sciences. 102 (1): 136–142. doi:10.1254/jphs.FP0060526. PMID 16974066.
Takenoshita S, Nishino S (June 2020). "Pharmacologic Management of Excessive Daytime Sleepiness". Sleep Med Clin. 15 (2): 177–194. doi:10.1016/j.jsmc.2020.02.006. PMID 32386693.
Boutrel B, Koob GF (September 2004). "What keeps us awake: the neuropharmacology of stimulants and wakefulness-promoting medications". Sleep. 27 (6): 1181–1194. doi:10.1093/sleep/27.6.1181. PMID 15532213.
Sherkat AA, Sardana N, Safaee S, Lehman EB, Craig TJ (February 2011). "The role of pseudoephedrine on daytime somnolence in patients suffering from perennial allergic rhinitis (PAR)". Ann Allergy Asthma Immunol. 106 (2): 97–102. doi:10.1016/j.anai.2010.11.013. PMID 21277510.
Gelotte CK, Albrecht HH, Hynson J, Gallagher V (December 2019). "A Multicenter, Randomized, Placebo-Controlled Study of Pseudoephedrine for the Temporary Relief of Nasal Congestion in Children With the Common Cold". J Clin Pharmacol. 59 (12): 1573–1583. doi:10.1002/jcph.1472. PMC 6851811. PMID 31274197.
Greenway F, Herber D, Raum W, Herber D, Morales S (July 1999). "Double-blind, randomized, placebo-controlled clinical trials with non-prescription medications for the treatment of obesity". Obes Res. 7 (4): 370–378. doi:10.1002/j.1550-8528.1999.tb00420.x. PMID 10440593.
Coulter AA, Rebello CJ, Greenway FL (July 2018). "Centrally Acting Agents for Obesity: Past, Present, and Future". Drugs. 78 (11): 1113–1132. doi:10.1007/s40265-018-0946-y. PMC 6095132. PMID 30014268.
Ioannides-Demos LL, Proietto J, McNeil JJ (2005). "Pharmacotherapy for obesity". Drugs. 65 (10): 1391–418. doi:10.2165/00003495-200565100-00006. PMID 15977970.
Fedorowski A, Melander O (April 2013). "Syndromes of orthostatic intolerance: a hidden danger". J Intern Med. 273 (4): 322–335. doi:10.1111/joim.12021. PMID 23216860.
Abed H, Ball PA, Wang LX (March 2012). "Diagnosis and management of postural orthostatic tachycardia syndrome: A brief review". J Geriatr Cardiol. 9 (1): 61–67. doi:10.3724/SP.J.1263.2012.00061. PMC 3390096. PMID 22783324.
Muneer A, Minhas S, Arya M, Ralph DJ (August 2008). "Stuttering priapism--a review of the therapeutic options". Int J Clin Pract. 62 (8): 1265–1270. doi:10.1111/j.1742-1241.2008.01780.x. PMID 18479367.
Culligan PJ, Heit M (December 2000). "Urinary incontinence in women: evaluation and management". American Family Physician. 62 (11): 2433–44, 2447, 2452. PMID 11130230. Archived from the original on 7 September 2023. Retrieved 7 September 2023.
Deckx L, De Sutter AI, Guo L, Mir NA, van Driel ML (October 2016). "Nasal decongestants in monotherapy for the common cold". The Cochrane Database of Systematic Reviews. 2016 (10): CD009612. doi:10.1002/14651858.CD009612.pub2. PMC 6461189. PMID 27748955.
Hughes DT, Empey DW, Land M (December 1983). "Effects of pseudoephedrine in man". J Clin Hosp Pharm. 8 (4): 315–321. doi:10.1111/j.1365-2710.1983.tb01053.x. PMID 6198336.
Vidal C, Prieto A, Pérez-Carral C, Armisén M (April 1998). "Nonpigmenting fixed drug eruption due to pseudoephedrine". Annals of Allergy, Asthma & Immunology. 80 (4): 309–310. doi:10.1016/S1081-1206(10)62974-2. PMID 9564979.
Webb J, Dubose J (2013). "Symptoms of major depression after pseudoephedrine withdrawal: a case report". J Neuropsychiatry Clin Neurosci. 25 (2): E54–E55. doi:10.1176/appi.neuropsych.12060138. PMID 23686066.
Freeman KB, Wang Z, Woolverton WL (April 2010). "Self-administration of (+)-methamphetamine and (+)-pseudoephedrine, alone and combined, by rhesus monkeys". Pharmacol Biochem Behav. 95 (2): 198–202. doi:10.1016/j.pbb.2010.01.005. PMC 2838499. PMID 20100506.
Wee S, Ordway GA, Woolverton WL (June 2004). "Reinforcing effect of pseudoephedrine isomers and the mechanism of action". Eur J Pharmacol. 493 (1–3): 117–125. doi:10.1016/j.ejphar.2004.04.030. PMID 15189772.
Tongjaroenbuangam W, Meksuriyen D, Govitrapong P, Kotchabhakdi N, Baldwin BA (February 1998). "Drug discrimination analysis of pseudoephedrine in rats". Pharmacol Biochem Behav. 59 (2): 505–510. doi:10.1016/s0091-3057(97)00459-0. PMID 9477001.
Akiba K, Satoh S, Matsumura H, Suzuki T, Kohno H, Tadano T, et al. (May 1982). "[Effect of d-pseudoephedrine on the central nervous system in mice]". Nihon Yakurigaku Zasshi (in Japanese). 79 (5): 401–408. doi:10.1254/fpj.79.401. PMID 6813205.
Diaz MA, Wise TN, Semchyshyn GO (September 1979). "Self-medication with pseudoephedrine in a chronically depressed patient". Am J Psychiatry. 136 (9): 1217–1218. doi:10.1176/ajp.136.9.1217. PMID 474820.
Stalker DJ, Jungbluth GL (2003). "Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial". Clin Pharmacokinet. 42 (13): 1129–1140. doi:10.2165/00003088-200342130-00004. PMID 14531724.
Jacob JE, Wagner ML, Sage JI (March 2003). "Safety of selegiline with cold medications". Ann Pharmacother. 37 (3): 438–441. doi:10.1345/aph.1C175. PMID 12639177.
Hendershot PE, Antal EJ, Welshman IR, Batts DH, Hopkins NK (May 2001). "Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorpan HBr". J Clin Pharmacol. 41 (5): 563–572. doi:10.1177/00912700122010302. PMID 11361053.
Azzaro AJ, VanDenBerg CM, Ziemniak J, Kemper EM, Blob LF, Campbell BJ (August 2007). "Evaluation of the potential for pharmacodynamic and pharmacokinetic drug interactions between selegiline transdermal system and two sympathomimetic agents (pseudoephedrine and phenylpropanolamine) in healthy volunteers". J Clin Pharmacol. 47 (8): 978–990. doi:10.1177/0091270007302950. PMID 17554106.
Johnson DA, Hricik JG (1993). "The pharmacology of alpha-adrenergic decongestants". Pharmacotherapy. 13 (6 Pt 2): 110S–115S, discussion 143S–146S. doi:10.1002/j.1875-9114.1993.tb02779.x. PMID 7507588.
Broadley KJ (March 2010). "The vascular effects of trace amines and amphetamines". Pharmacol Ther. 125 (3): 363–375. doi:10.1016/j.pharmthera.2009.11.005. PMID 19948186. It is also relevant to other sympathomimetic amines contained in over-the-counter cough and cold remedies as decongestants, such as phenylpropanolamine and pseudoephedrine. Thus, MAO inhibitors potentiate the peripheral effects of indirectly acting sympathomimetic amines. It is not often realized, however, that this potentiation occurs irrespective of whether the amine is a substrate for MAO. An α-methyl group on the side chain, as in amphetamine and ephedrine, renders the amine immune to deamination so that they are not metabolized in the gut. Similarly, β-PEA would not be deaminated in the gut as it is a selective substrate for MAO-B which is not found in the gut. However, MAO inhibition in sympathetic neurones allows the cytoplasmic pool of noradrenaline to increase. It is this pool that is released by indirectly acting sympathomimetic amines and their responses are therefore potentiated irrespective of whether they are deaminated by MAO (Youdim & Finberg, 1991).
Pederson KJ, Kuntz DH, Garbe GJ (May 2001). "Acute myocardial ischemia associated with ingestion of bupropion and pseudoephedrine in a 21-year-old man". Can J Cardiol. 17 (5): 599–601. PMID 11381283.
Mariani PJ (March 1986). "Pseudoephedrine-induced hypertensive emergency: treatment with labetalol". Am J Emerg Med. 4 (2): 141–142. doi:10.1016/0735-6757(86)90159-2. PMID 3947442.
Mores N, Campia U, Navarra P, Cardillo C, Preziosi P (June 1999). "No cardiovascular effects of single-dose pseudoephedrine in patients with essential hypertension treated with beta-blockers". Eur J Clin Pharmacol. 55 (4): 251–254. doi:10.1007/s002280050624. PMID 10424315.
Gad MZ, Azab SS, Khattab AR, Farag MA (October 2021). "Over a century since ephedrine discovery: an updated revisit to its pharmacological aspects, functionality and toxicity in comparison to its herbal extracts". Food Funct. 12 (20): 9563–9582. doi:10.1039/d1fo02093e. PMID 34533553.
Kobayashi S, Endou M, Sakuraya F, Matsuda N, Zhang XH, Azuma M, et al. (November 2003). "The sympathomimetic actions of l-ephedrine and d-pseudoephedrine: direct receptor activation or norepinephrine release?". Anesth Analg. 97 (5): 1239–1245. doi:10.1213/01.ANE.0000092917.96558.3C. PMID 14570629.
Rothman RB, Baumann MH (2003). "Monoamine transporters and psychostimulant drugs". Eur. J. Pharmacol. 479 (1–3): 23–40. doi:10.1016/j.ejphar.2003.08.054. PMID 14612135.
Rothman RB, Baumann MH (2006). "Therapeutic potential of monoamine transporter substrates". Curr Top Med Chem. 6 (17): 1845–1859. doi:10.2174/156802606778249766. PMID 17017961.
Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, et al. (January 2001). "Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin". Synapse. 39 (1): 32–41. doi:10.1002/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3. PMID 11071707.
Baumann MH, Partilla JS, Lehner KR, Thorndike EB, Hoffman AF, Holy M, et al. (2013). "Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products". Neuropsychopharmacology. 38 (4): 552–562. doi:10.1038/npp.2012.204. PMC 3572453. PMID 23072836.
Baumann MH, Ayestas MA, Partilla JS, Sink JR, Shulgin AT, Daley PF, et al. (April 2012). "The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue". Neuropsychopharmacology. 37 (5): 1192–203. doi:10.1038/npp.2011.304. PMC 3306880. PMID 22169943.
Rothman RB, Baumann MH (December 2005). "Targeted screening for biogenic amine transporters: potential applications for natural products". Life Sci. 78 (5): 512–518. doi:10.1016/j.lfs.2005.09.001. PMID 16202429.
Vansal SS, Feller DR (September 1999). "Direct effects of ephedrine isomers on human beta-adrenergic receptor subtypes". Biochem Pharmacol. 58 (5): 807–810. doi:10.1016/s0006-2952(99)00152-5. PMID 10449190.
Drew CD, Knight GT, Hughes DT, Bush M (September 1978). "Comparison of the effects of D-(-)-ephedrine and L-(+)-pseudoephedrine on the cardiovascular and respiratory systems in man". British Journal of Clinical Pharmacology. 6 (3): 221–225. doi:10.1111/j.1365-2125.1978.tb04588.x. PMC 1429447. PMID 687500.
Ulus IH, Maher TJ, Wurtman RJ (June 2000). "Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors". Biochem Pharmacol. 59 (12): 1611–1621. doi:10.1016/s0006-2952(00)00306-3. PMID 10799660.
Sica DA, Comstock TJ (October 1989). "Pseudoephedrine accumulation in renal failure". Am J Med Sci. 298 (4): 261–263. doi:10.1097/00000441-198910000-00010. PMID 2801760.
Lyon CC, Turney JH (1996). "Pseudoephedrine toxicity in renal failure". Br J Clin Pract. 50 (7): 396–397. doi:10.1111/j.1742-1241.1996.tb09584.x. PMID 9015914.
Kril MB, Fung HL (May 1990). "Influence of hydrophobicity on the ion exchange selectivity coefficients for aromatic amines". J Pharm Sci. 79 (5): 440–443. doi:10.1002/jps.2600790517. PMID 2352166.
Bharate SS, Mignani S, Vishwakarma RA (December 2018). "Why Are the Majority of Active Compounds in the CNS Domain Natural Products? A Critical Analysis". J Med Chem. 61 (23): 10345–10374. doi:10.1021/acs.jmedchem.7b01922. PMID 29989814.
Schep LJ, Slaughter RJ, Beasley DM (August 2010). "The clinical toxicology of metamfetamine". Clin Toxicol (Phila). 48 (7): 675–694. doi:10.3109/15563650.2010.516752. PMID 20849327. Metamfetamine acts in a manner similar to amfetamine, but with the addition of the methyl group to the chemical structure. It is more lipophilic (Log p value 2.07, compared with 1.76 for amfetamine),⁴ thereby enabling rapid and extensive transport across the blood–brain barrier.¹⁹
Froese L, Dian J, Gomez A, Unger B, Zeiler FA (October 2020). "The cerebrovascular response to norepinephrine: A scoping systematic review of the animal and human literature". Pharmacol Res Perspect. 8 (5): e00655. doi:10.1002/prp2.655. PMC 7510331. PMID 32965778.
Pajouhesh H, Lenz GR (October 2005). "Medicinal chemical properties of successful central nervous system drugs". NeuroRx. 2 (4): 541–553. doi:10.1602/neurorx.2.4.541. PMC 1201314. PMID 16489364. Lipophilicity was the first of the descriptors to be identified as important for CNS penetration. Hansch and Leo54 reasoned that highly lipophilic molecules will partitioned into the lipid interior of membranes and will be retained there. However, ClogP correlates nicely with LogBBB with increasing lipophilicity increasing brain penetration. For several classes of CNS active substances, Hansch and Leo54 found that blood-brain barrier penetration is optimal when the LogP values are in the range of 1.5-2.7, with the mean value of 2.1. An analysis of small drug-like molecules suggested that for better brain permeation46 and for good intestinal permeability55 the LogD values need to be greater than 0 and less than 3. In comparison, the mean value for ClogP for the marketed CNS drugs is 2.5, which is in good agreement with the range found by Hansch et al.22
Patil PN, Tye A, Lapidus JB (May 1965). "A Pharmacological Study of the Ephedrine Isomers". The Journal of Pharmacology and Experimental Therapeutics. 148 (2): 158–168. PMID 14301006. Archived from the original on 7 January 2020. Retrieved 24 December 2009.
Boland DM, Rein J, Lew EO, Hearn WL (October 2003). "Fatal cold medication intoxication in an infant". Journal of Analytical Toxicology. 27 (7): 523–526. doi:10.1093/jat/27.7.523. PMID 14607011.
Oliver AL, Anderson BN, Roddick FA (1999). "Factors affecting the production of L-phenylacetylcarbinol by yeast: a case study". Advances in Microbial Physiology. Vol. 41. pp. 1–45. doi:10.1016/S0065-2911(08)60164-2. ISBN 978-0-12-027741-4. PMID 10500843.
Kalix P (April 1991). "The pharmacology of psychoactive alkaloids from ephedra and catha". J Ethnopharmacol. 32 (1–3): 201–208. doi:10.1016/0378-8741(91)90119-x. PMID 1881158.
Strano-Rossi S, Leone D, de la Torre X, Botrè F (August 2009). "The relevance of the urinary concentration of ephedrines in anti-doping analysis: determination of pseudoephedrine, cathine, and ephedrine after administration of over-the-counter medicaments". Therapeutic Drug Monitoring. 31 (4): 520–526. doi:10.1097/FTD.0b013e3181ac6006. PMID 19571776. S2CID 21333203.
Jolley D, Dawson B, Maloney SK, White J, Goodman C, Peeling P (June 2014). "Hydration and urinary pseudoephedrine levels after a simulated team game". International Journal of Sport Nutrition and Exercise Metabolism. 24 (3): 325–332. doi:10.1123/ijsnem.2013-0076. PMID 24458099.
Hatton RC, Winterstein AG, McKelvey RP, Shuster J, Hendeles L (March 2007). "Efficacy and safety of oral phenylephrine: systematic review and meta-analysis". The Annals of Pharmacotherapy. 41 (3): 381–390. doi:10.1345/aph.1H679. PMID 17264159. S2CID 25627664.
Horak F, Zieglmayer P, Zieglmayer R, Lemell P, Yao R, Staudinger H, et al. (February 2009). "A placebo-controlled study of the nasal decongestant effect of phenylephrine and pseudoephedrine in the Vienna Challenge Chamber". Annals of Allergy, Asthma & Immunology. 102 (2): 116–120. doi:10.1016/S1081-1206(10)60240-2. PMID 19230461.
Achuthan S, Medhi B (September 2015). "A systematic review of the pharmacological approaches against snoring: can we count on the chickens that have hatched?". Sleep Breath. 19 (3): 1035–1042. doi:10.1007/s11325-015-1123-0. PMID 25680547.
Trimeloni L, Spencer J (2016). "Diagnosis and Management of Breast Milk Oversupply". J Am Board Fam Med. 29 (1): 139–142. doi:10.3122/jabfm.2016.01.150164. PMID 26769886.
Aljazaf K, Hale TW, Ilett KF, Hartmann PE, Mitoulas LR, Kristensen JH, et al. (July 2003). "Pseudoephedrine: effects on milk production in women and estimation of infant exposure via breastmilk". British Journal of Clinical Pharmacology. 56 (1): 18–24. doi:10.1046/j.1365-2125.2003.01822.x. PMC 1884328. PMID 12848771.

ncbi.nlm.nih.gov

Głowacka K, Wiela-Hojeńska A (May 2021). "Pseudoephedrine—Benefits and Risks". Int J Mol Sci. 22 (10): 5146. doi:10.3390/ijms22105146. PMC 8152226. PMID 34067981.
Eccles R (January 2007). "Substitution of phenylephrine for pseudoephedrine as a nasal decongeststant. An illogical way to control methamphetamine abuse". British Journal of Clinical Pharmacology. 63 (1): 10–14. doi:10.1111/j.1365-2125.2006.02833.x. PMC 2000711. PMID 17116124.
Schifano F, Chiappini S, Miuli A, Mosca A, Santovito MC, Corkery JM, et al. (2021). "Focus on Over-the-Counter Drugs' Misuse: A Systematic Review on Antihistamines, Cough Medicines, and Decongestants". Front Psychiatry. 12: 657397. doi:10.3389/fpsyt.2021.657397. PMC 8138162. PMID 34025478.
Munafò A, Frara S, Perico N, Di Mauro R, Cortinovis M, Burgaletto C, et al. (December 2021). "In search of an ideal drug for safer treatment of obesity: The false promise of pseudoephedrine". Rev Endocr Metab Disord. 22 (4): 1013–1025. doi:10.1007/s11154-021-09658-w. PMC 8724077. PMID 33945051.
Trinh KV, Kim J, Ritsma A (2015). "Effect of pseudoephedrine in sport: a systematic review". BMJ Open Sport Exerc Med. 1 (1): e000066. doi:10.1136/bmjsem-2015-000066. PMC 5117033. PMID 27900142.
Gheorghiev MD, Hosseini F, Moran J, Cooper CE (October 2018). "Effects of pseudoephedrine on parameters affecting exercise performance: a meta-analysis". Sports Med Open. 4 (1): 44. doi:10.1186/s40798-018-0159-7. PMC 6173670. PMID 30291523.
Gelotte CK, Albrecht HH, Hynson J, Gallagher V (December 2019). "A Multicenter, Randomized, Placebo-Controlled Study of Pseudoephedrine for the Temporary Relief of Nasal Congestion in Children With the Common Cold". J Clin Pharmacol. 59 (12): 1573–1583. doi:10.1002/jcph.1472. PMC 6851811. PMID 31274197.
Coulter AA, Rebello CJ, Greenway FL (July 2018). "Centrally Acting Agents for Obesity: Past, Present, and Future". Drugs. 78 (11): 1113–1132. doi:10.1007/s40265-018-0946-y. PMC 6095132. PMID 30014268.
Abed H, Ball PA, Wang LX (March 2012). "Diagnosis and management of postural orthostatic tachycardia syndrome: A brief review". J Geriatr Cardiol. 9 (1): 61–67. doi:10.3724/SP.J.1263.2012.00061. PMC 3390096. PMID 22783324.
Deckx L, De Sutter AI, Guo L, Mir NA, van Driel ML (October 2016). "Nasal decongestants in monotherapy for the common cold". The Cochrane Database of Systematic Reviews. 2016 (10): CD009612. doi:10.1002/14651858.CD009612.pub2. PMC 6461189. PMID 27748955.
Freeman KB, Wang Z, Woolverton WL (April 2010). "Self-administration of (+)-methamphetamine and (+)-pseudoephedrine, alone and combined, by rhesus monkeys". Pharmacol Biochem Behav. 95 (2): 198–202. doi:10.1016/j.pbb.2010.01.005. PMC 2838499. PMID 20100506.
Baumann MH, Partilla JS, Lehner KR, Thorndike EB, Hoffman AF, Holy M, et al. (2013). "Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products". Neuropsychopharmacology. 38 (4): 552–562. doi:10.1038/npp.2012.204. PMC 3572453. PMID 23072836.
Baumann MH, Ayestas MA, Partilla JS, Sink JR, Shulgin AT, Daley PF, et al. (April 2012). "The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue". Neuropsychopharmacology. 37 (5): 1192–203. doi:10.1038/npp.2011.304. PMC 3306880. PMID 22169943.
Drew CD, Knight GT, Hughes DT, Bush M (September 1978). "Comparison of the effects of D-(-)-ephedrine and L-(+)-pseudoephedrine on the cardiovascular and respiratory systems in man". British Journal of Clinical Pharmacology. 6 (3): 221–225. doi:10.1111/j.1365-2125.1978.tb04588.x. PMC 1429447. PMID 687500.
Froese L, Dian J, Gomez A, Unger B, Zeiler FA (October 2020). "The cerebrovascular response to norepinephrine: A scoping systematic review of the animal and human literature". Pharmacol Res Perspect. 8 (5): e00655. doi:10.1002/prp2.655. PMC 7510331. PMID 32965778.
Pajouhesh H, Lenz GR (October 2005). "Medicinal chemical properties of successful central nervous system drugs". NeuroRx. 2 (4): 541–553. doi:10.1602/neurorx.2.4.541. PMC 1201314. PMID 16489364. Lipophilicity was the first of the descriptors to be identified as important for CNS penetration. Hansch and Leo54 reasoned that highly lipophilic molecules will partitioned into the lipid interior of membranes and will be retained there. However, ClogP correlates nicely with LogBBB with increasing lipophilicity increasing brain penetration. For several classes of CNS active substances, Hansch and Leo54 found that blood-brain barrier penetration is optimal when the LogP values are in the range of 1.5-2.7, with the mean value of 2.1. An analysis of small drug-like molecules suggested that for better brain permeation46 and for good intestinal permeability55 the LogD values need to be greater than 0 and less than 3. In comparison, the mean value for ClogP for the marketed CNS drugs is 2.5, which is in good agreement with the range found by Hansch et al.22
Aljazaf K, Hale TW, Ilett KF, Hartmann PE, Mitoulas LR, Kristensen JH, et al. (July 2003). "Pseudoephedrine: effects on milk production in women and estimation of infant exposure via breastmilk". British Journal of Clinical Pharmacology. 56 (1): 18–24. doi:10.1046/j.1365-2125.2003.01822.x. PMC 1884328. PMID 12848771.

pubchem.ncbi.nlm.nih.gov

"Pseudoephedrine". PubChem. Retrieved 25 July 2024.
"Amphetamine". PubChem. Retrieved 26 July 2024.
"Ephedrine". PubChem. Retrieved 26 July 2024.
"Norephedrine". PubChem. Retrieved 26 July 2024.
"Phenylephrine". PubChem. Retrieved 21 July 2024.
"Norepinephrine". PubChem. Retrieved 26 July 2024.

nplexservice.com

"NPLEx – National Precursor Log Exchange". www.nplexservice.com. Archived from the original on 12 October 2015. Retrieved 24 October 2015.

nytimes.com

Bovett R (15 November 2010). "How to Kill the Meth Monster". The New York Times. Archived from the original on 1 May 2011. Retrieved 16 November 2010.

olympic.org

"IOC issues a reprimand against Slovakian ice hockey player". Archived from the original on 8 March 2014. Retrieved 24 February 2014.
"IOC Decision – Swedish ice hockey player Nicklas Backstrom to receive Sochi silver medal". IOC. 14 March 2014. Archived from the original on 15 March 2014. Retrieved 14 March 2014.

oregondec.org

"Oregon Meth Lab Incident Statistics" (PDF). Oregon Alliance for Drug Endangered Children (OregonDEC). Archived from the original (PDF) on 6 March 2012.

oregonlive.com

"Search OregonLive.com". The Oregonian. Archived from the original on 17 August 2016. Retrieved 13 December 2010.
"How Legislation Changed Meth Purity" (PDF). The Oregonian. Archived from the original (PDF) on 15 November 2011. Retrieved 13 December 2010.

papharmacists.com

"DEA Interim Final Regulation: Ephedrine, Pseudoephedrine, and Phenylpropanolamine Requirements" (PDF). Archived from the original (PDF) on 18 October 2006.

parliament.nz

"Misuse of Drugs Amendment Bill". parliament.nz. Archived from the original on 6 July 2017. Retrieved 6 July 2017.

postimees.ee

sakala.postimees.ee

"Keskmise eestlase kodust leiab portsu dopingut". Uudised (in Estonian). 28 October 2016. Archived from the original on 9 July 2023. Retrieved 9 July 2023.

prnewswire.com

"Target Announces That All Products Containing Pseudoephedrine Will Be Placed Behind Pharmacy Counter". PRNewswire. Archived from the original on 31 January 2016. Retrieved 24 January 2016.

pulseit.news

"Project STOP mandatory for pharmacists in NSW from next month". Pulse.IT. 24 February 2016. Retrieved 11 July 2024.

researchgate.net

"Elimination of ephedrines in urine following multiple dosing the consequences for athletes in relation to doping control". Archived from the original on 29 August 2021. Retrieved 24 February 2014.

rnz.co.nz

"Bill to make pseudoephedrine-based medicines available over-the-counter passes third reading". RNZ. 9 April 2024. Retrieved 4 June 2024.

sante.fr

ansm.sante.fr

"En cas de rhume, évitez les médicaments vasoconstricteurs par voie orale !". Agence nationale de sécurité du médicament et des produits de santé. 22 October 2023. Retrieved 2 December 2024.

semanticscholar.org

api.semanticscholar.org

Hatton RC, Hendeles L (March 2022). "Why Is Oral Phenylephrine on the Market After Compelling Evidence of Its Ineffectiveness as a Decongestant?". Ann Pharmacother. 56 (11): 1275–1278. doi:10.1177/10600280221081526. PMID 35337187. S2CID 247712448.
Strano-Rossi S, Leone D, de la Torre X, Botrè F (August 2009). "The relevance of the urinary concentration of ephedrines in anti-doping analysis: determination of pseudoephedrine, cathine, and ephedrine after administration of over-the-counter medicaments". Therapeutic Drug Monitoring. 31 (4): 520–526. doi:10.1097/FTD.0b013e3181ac6006. PMID 19571776. S2CID 21333203.
Hatton RC, Winterstein AG, McKelvey RP, Shuster J, Hendeles L (March 2007). "Efficacy and safety of oral phenylephrine: systematic review and meta-analysis". The Annals of Pharmacotherapy. 41 (3): 381–390. doi:10.1345/aph.1H679. PMID 17264159. S2CID 25627664.

semissourian.com

"Cape Girardeau City Council passes prescription requirement for pseudoephedrine". The Southeast Missourian. 7 December 2010. Archived from the original on 28 January 2011. Retrieved 10 December 2010.

therapeuticresearch.com

pharmacytechniciansletter.therapeuticresearch.com

"What ingredients are commonly found in OTC cough and cold products? What do they do?". Pharmacy Technician's Letter. Archived from the original on 25 October 2015. Retrieved 25 August 2015.

tribstar.com

Trigg L (20 May 2010). "Four Valley pharmacies to require prescriptions for certain products to help fight meth problem". Terre Haute Tribune-Star. Archived from the original on 24 May 2010. Retrieved 28 May 2010. (Subscription required, free access for first 30 days)

tsn.ca

"Sweden's Bäckström tests positive for banned substance". Archived from the original on 27 February 2014. Retrieved 24 February 2014.

turkishjournalpediatrics.org

"Acute urinary retention due to pseudoephedrine hydrochloride in a 3-year-old child". The Turkish Journal of Pediatrics. Archived from the original on 14 August 2016. Retrieved 12 August 2015.

usdoj.gov

deadiversion.usdoj.gov

"CMEA (The Combat Methamphetamine Epidemic Act of 2005)". DEA Diversion Control Division. 14 July 2017. Archived from the original on 17 February 2020. Retrieved 17 February 2020. This article incorporates text from this source, which is in the public domain.
"2011 – Final Rule: Implementation of the Methamphetamine Production Prevention Act of 2008". DEA Diversion Control Division. 1 November 2011. Archived from the original on 17 February 2020. Retrieved 17 February 2020. This article incorporates text from this source, which is in the public domain.

uwa.edu.au

research-repository.uwa.edu.au

Jolley D, Dawson B, Maloney SK, White J, Goodman C, Peeling P (June 2014). "Hydration and urinary pseudoephedrine levels after a simulated team game". International Journal of Sport Nutrition and Exercise Metabolism. 24 (3): 325–332. doi:10.1123/ijsnem.2013-0076. PMID 24458099.

vidal.fr

Paitraud D (9 April 2024). "Pas de pseudoéphédrine pour un rhume : l'ANSM alerte à nouveau les professionnels de santé". VIDAL. Retrieved 2 December 2024.

wada-ama.org

"WADA 2010 Prohibited List Now Published – World Anti-Doping Agency". Wada-ama.org. Archived from the original on 20 February 2012. Retrieved 6 May 2012.
"Ressources" (PDF). Archived from the original (PDF) on 29 May 2014. Retrieved 18 August 2016.

walgreens.com

"Pseudoephedrine Compliance". Walgreens. Archived from the original on 30 January 2016. Retrieved 24 January 2016.

washingtonpost.com

Prewitt A (15 January 2015). "Nicklas Backstrom's Olympic doping appeal resolved with reprimand". The Washington Post. Archived from the original on 17 January 2015. Retrieved 18 January 2015.

web.archive.org

Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 15 August 2023.
"The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
"American Urological Association – Medical Student Curriculum – Urinary Incontinence". American Urological Association. Archived from the original on 9 July 2015. Retrieved 12 August 2015.
"Acute urinary retention due to pseudoephedrine hydrochloride in a 3-year-old child". The Turkish Journal of Pediatrics. Archived from the original on 14 August 2016. Retrieved 12 August 2015.
Weiss BD (15 January 2005). "Selecting Medications for the Treatment of Urinary Incontinence – January 15, 2005 – American Family Physician". American Family Physician. 71 (2): 315–322. Archived from the original on 7 July 2022. Retrieved 6 May 2012.
Culligan PJ, Heit M (December 2000). "Urinary incontinence in women: evaluation and management". American Family Physician. 62 (11): 2433–44, 2447, 2452. PMID 11130230. Archived from the original on 7 September 2023. Retrieved 7 September 2023.
"Adco-Tussend". Home.intekom.com. 15 March 1993. Archived from the original on 30 April 2012. Retrieved 6 May 2012.
Patil PN, Tye A, Lapidus JB (May 1965). "A Pharmacological Study of the Ephedrine Isomers". The Journal of Pharmacology and Experimental Therapeutics. 148 (2): 158–168. PMID 14301006. Archived from the original on 7 January 2020. Retrieved 24 December 2009.
Proposed International Non-Proprietary Names (Prop. I.N.N.): List 11 WHO Chronicle, Vol. 15, No. 8, August 1961, pp. 314–20
Baselt R (2008). Disposition of Toxic Drugs and Chemicals in Man (8th ed.). Foster City, California: Biomedical Publications. pp. 1344–1346. Archived from the original on 4 December 2020. Retrieved 19 August 2010.
"Clamp down on shipments of raw ingredients, Oregonian, Press, Congressional Caucus to Fight and Control Methamphetamine". U.S. House of Representatives. 31 August 2005. Archived from the original on 9 May 2006. Retrieved 7 September 2023.
Ladenburg A, Oelschlägel C (1889). "Ueber das "Pseudo-Ephedrin"" [On pseudo-ephedrine]. Berichte der Deutschen Chemischen Gesellschaft (in German). 22 (2): 1823–1827. doi:10.1002/cber.18890220225. Archived from the original on 8 March 2021. Retrieved 19 May 2019.
"Pseudoephedrine". 26 April 2016. Archived from the original on 29 May 2016. Retrieved 25 July 2024.{{cite web}}: CS1 maint: unfit URL (link)
"Benadryl Allergy Relief Plus Decongestant Capsules - Summary of Product Characteristics (SmPC) - (emc)". www.medicines.org.uk. Datapharm. Archived from the original on 22 November 2023. Retrieved 22 November 2023.
"Drug Pamphlet: Congestal". 12 February 2017. Archived from the original on 13 December 2018. Retrieved 13 December 2018.
"Photographic image of Congestal tablets information sheet" (JPG). 1.bp.blogspot.com. Archived from the original on 13 December 2018. Retrieved 28 February 2022.
"WADA 2010 Prohibited List Now Published – World Anti-Doping Agency". Wada-ama.org. Archived from the original on 20 February 2012. Retrieved 6 May 2012.
"Elimination of ephedrines in urine following multiple dosing the consequences for athletes in relation to doping control". Archived from the original on 29 August 2021. Retrieved 24 February 2014.
"Ressources" (PDF). Archived from the original (PDF) on 29 May 2014. Retrieved 18 August 2016.
"Silken tests positive". Archived from the original on 4 March 2014. Retrieved 24 February 2014.
"2000 World Championships – Pairs". Ice Skating International. Archived from the original on 14 November 2011. Retrieved 6 June 2010.
"Summer Olympics 2000 Raducan tests positive for stimulant". ESPN. 26 September 2000. Archived from the original on 2 October 2011. Retrieved 6 May 2012.
"Amanar Tops Romanian Money List". International Gymnast Magazine Online. 15 October 2000. Archived from the original on 15 July 2001. Retrieved 6 May 2012.
"IOC issues a reprimand against Slovakian ice hockey player". Archived from the original on 8 March 2014. Retrieved 24 February 2014.
"Sweden's Bäckström tests positive for banned substance". Archived from the original on 27 February 2014. Retrieved 24 February 2014.
"IOC Decision – Swedish ice hockey player Nicklas Backstrom to receive Sochi silver medal". IOC. 14 March 2014. Archived from the original on 15 March 2014. Retrieved 14 March 2014.
Prewitt A (15 January 2015). "Nicklas Backstrom's Olympic doping appeal resolved with reprimand". The Washington Post. Archived from the original on 17 January 2015. Retrieved 18 January 2015.
"Legal Requirements for the Sale and Purchase of Drug Products Containing Pseudoephedrine, Ephedrine, and Phenylpropanolamine". U.S. Food and Drug Administration. 9 March 2006. Archived from the original on 25 December 2023. Retrieved 7 September 2023. This article incorporates text from this source, which is in the public domain.
"CMEA (The Combat Methamphetamine Epidemic Act of 2005)". DEA Diversion Control Division. 14 July 2017. Archived from the original on 17 February 2020. Retrieved 17 February 2020. This article incorporates text from this source, which is in the public domain.
"2011 – Final Rule: Implementation of the Methamphetamine Production Prevention Act of 2008". DEA Diversion Control Division. 1 November 2011. Archived from the original on 17 February 2020. Retrieved 17 February 2020. This article incorporates text from this source, which is in the public domain.
"Pseudoephedrine Compliance". Walgreens. Archived from the original on 30 January 2016. Retrieved 24 January 2016.
"Target Announces That All Products Containing Pseudoephedrine Will Be Placed Behind Pharmacy Counter". PRNewswire. Archived from the original on 31 January 2016. Retrieved 24 January 2016.
"Microsoft Word - RedListE2007.doc" (PDF). Archived from the original (PDF) on 27 February 2008. Retrieved 6 May 2012.
"Project STOP video – Online Advertising". Innovationrx.com.au. Archived from the original on 26 April 2012. Retrieved 6 May 2012.
"PRAC February 2023 – Start of a safety review of pseudoephedrine-containing medicines | FAMHP". www.famhp.be. Archived from the original on 15 August 2023. Retrieved 15 August 2023.
"Archived – Health Canada Reminds Canadians not to use Ephedra/Ephedrine Products". healthycanadians.gc.ca. 20 August 2021. Archived from the original on 27 April 2014. Retrieved 1 July 2015.
"What ingredients are commonly found in OTC cough and cold products? What do they do?". Pharmacy Technician's Letter. Archived from the original on 25 October 2015. Retrieved 25 August 2015.
"Family Health Online – Family Health Magazine -PHARMACY CARE – Over-the-Counter Medication – Why must I ask for that?". Archived from the original on 18 June 2016. Retrieved 18 August 2016.
"Gobierno prohĂbe antigripales con pseudoefedrina a partir de finales de 2010 – Archivo – Archivo Digital de Noticias de Colombia y el Mundo desde 1.990" [Government Prohibits Flu Pseudoephedrine in Late 2010 – Archive – News Archive Digital Colombia and the World since 1990] (in Spanish). Eltiempo.com. 8 July 2009 [Published 11 August 2009]. Archived from the original on 21 May 2011. Retrieved 6 May 2012.
"Keskmise eestlase kodust leiab portsu dopingut". Uudised (in Estonian). 28 October 2016. Archived from the original on 9 July 2023. Retrieved 9 July 2023.
"Kysy Kiminkiseltä: Parasta flunssan hoitoa on lepo ja mummon mustaviinimarjamehu". www.apu.fi. 29 January 2018. Archived from the original on 9 July 2023. Retrieved 9 July 2023.
"Customs Information". Consulate-General of Japan in Seattle. Archived from the original on 19 August 2015. Retrieved 27 August 2015.
"Prohibirán definitivamente uso de pseudoefedrina" [A Permanent Ban on Pseudoephedrine] (in Spanish). 23 November 2007 [Published 2 December 2007]. Archived from the original on 19 December 2013. Retrieved 17 December 2013.
Megget K (2 September 2007). "Pseudoephedrine drugs still OTC". Archived from the original on 29 August 2021. Retrieved 15 October 2018.
"Ephedrine and Pseudoephedrine to Become Controlled Drugs". Medsafe, New Zealand Medicines and Medical Devices Safety Authority. Archived from the original on 8 March 2007.
"Chemical Brothers". Listener (New Zealand). Archived from the original on 23 May 2010.
"Misuse of Drugs Amendment Bill". parliament.nz. Archived from the original on 6 July 2017. Retrieved 6 July 2017.
"Kontrole Tabi İlaçlar" (PDF). Social Security Institution of Republic of Turkey. July 2013. Archived from the original (PDF) on 11 March 2014. Retrieved 11 March 2014.
"Drug Safety Update, March 2008". The Medicines and Healthcare products Regulatory Agency and the Commission on Human Medicines. 30 June 2008. Archived from the original (PDF) on 14 June 2011.
"Search OregonLive.com". The Oregonian. Archived from the original on 17 August 2016. Retrieved 13 December 2010.
"How Legislation Changed Meth Purity" (PDF). The Oregonian. Archived from the original (PDF) on 15 November 2011. Retrieved 13 December 2010.
"DEA Interim Final Regulation: Ephedrine, Pseudoephedrine, and Phenylpropanolamine Requirements" (PDF). Archived from the original (PDF) on 18 October 2006.
"State Ephedrine and Pseudoephedrine Single Over-The-Counter Transaction Limits". Namsdl.org. National Alliance for Model State Drug Laws (NAMSDL). 2013. Archived from the original (PDF) on 14 April 2016. Retrieved 3 December 2016.
"State Daily Gram Limits for Over-The-Counter Transactions Involving Ephedrine and Pseudoephedrine". Namsdl.org. National Alliance for Model State Drug Laws (NAMSDL). 2013. Archived from the original (PDF) on 14 August 2016. Retrieved 3 December 2016.
"State 30 Day Gram Limits for Over-The-Counter Transactions Involving Ephedrine and Pseudoephedrine". Namsdl.org. National Alliance for Model State Drug Laws (NAMSDL). 2013. Archived from the original (PDF) on 15 August 2016. Retrieved 3 December 2016.
"Nebraskans to sign for Sudafed". Lincoln Journal-Star. 13 March 2006. Archived from the original on 22 June 2018. Retrieved 20 August 2012.
"The National Alliance for Model State Drug Laws (NAMSDL) – Issues and Events". www.namsdl.org. Archived from the original on 3 October 2015. Retrieved 24 October 2015.
"MS Senate passes bill to restrict pseudoephedrine sales". Associated Content. WLOX. 2 February 2010. Archived from the original on 28 September 2011. Retrieved 8 May 2010.
Bovett R (15 November 2010). "How to Kill the Meth Monster". The New York Times. Archived from the original on 1 May 2011. Retrieved 16 November 2010.
"Oregon Meth Lab Incident Statistics" (PDF). Oregon Alliance for Drug Endangered Children (OregonDEC). Archived from the original (PDF) on 6 March 2012.
"DEA, Maps of Methamphetamine Lab Incidents". Justice.gov. Archived from the original on 10 September 2012. Retrieved 6 May 2012.
"Council Passes Law Restricting Pseudoephedrine". The Washington Missourian. 7 July 2009. Archived from the original on 12 March 2012. Retrieved 10 December 2010.
"Union Board Approves Pseudoephedrine Ordinance". The Washington Missourian. 13 October 2009. Archived from the original on 12 March 2012. Retrieved 10 December 2010.
"New Haven Passes Prescription Law". The Washington Missourian. 11 November 2010. Archived from the original on 12 March 2012. Retrieved 10 December 2010.
"Cape Girardeau City Council passes prescription requirement for pseudoephedrine". The Southeast Missourian. 7 December 2010. Archived from the original on 28 January 2011. Retrieved 10 December 2010.
"Ozark passes pseudoephedrine ban: Drug now prescription-only". CCHeadliner.com. 18 June 2013. Archived from the original on 24 February 2021. Retrieved 17 December 2013.
Trigg L (20 May 2010). "Four Valley pharmacies to require prescriptions for certain products to help fight meth problem". Terre Haute Tribune-Star. Archived from the original on 24 May 2010. Retrieved 28 May 2010. (Subscription required, free access for first 30 days)
"NPLEx – National Precursor Log Exchange". www.nplexservice.com. Archived from the original on 12 October 2015. Retrieved 24 October 2015.

wlox.com

"MS Senate passes bill to restrict pseudoephedrine sales". Associated Content. WLOX. 2 February 2010. Archived from the original on 28 September 2011. Retrieved 8 May 2010.

worldcat.org

search.worldcat.org

Freeman R, Kaufmann H (2007). "Disorders of Orthostatic Tolerance—Orthostatic Hypotension, Postural Tachycardia Syndrome, and Syncope". Continuum: Lifelong Learning in Neurology. 13: 50–88. doi:10.1212/01.CON.0000299966.05395.6c. ISSN 1080-2371.
Patrick KS, Markowitz JS (1997). "Pharmacology of methylphenidate, amphetamine enantiomers and pemoline in attention-deficit hyperactivity disorder". Human Psychopharmacology: Clinical and Experimental. 12 (6): 527–546. doi:10.1002/(SICI)1099-1077(199711/12)12:6<527::AID-HUP932>3.0.CO;2-U. ISSN 0885-6222.